UPDATE 3-Nestle invests $200 mln more in Aimmune after peanut allergy drug approval
February 05, 2020 at 13:30 PM EST
Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted as a potential blockbuster.